http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Sat, 24 Jun 2017 23:19:58 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - GW Pharma posts more good data from epilepsy trials ]]> http://www.proactiveinvestors.co.uk/companies/news/169972/gw-pharma-posts-more-good-data-from-epilepsy-trials-169972.html Cannabinoid product developer GW Pharmaceuticals PLC (Nasdaq:GWPH) has revealed more good phase III data for its Epidiolex drug for epilepsy sufferers.

In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo during both the 14 week treatment period and 12 week maintenance period.

 “We are pleased to present key findings from two pivotal Phase 3 studies of Epidiolex and believe these additional positive data reinforce the robust nature of the results achieved in two of the most difficult-to-treat epilepsy patient populations,” said Justin Gover, GW’s chief executive.

He added it was making good progress both towards a new drug admission for Epidiolex in the US and a commercial launch.

Orrin Devinsky, principal investigator of the Dravet syndrome trial, said he and his colleagues were excited by the prospect of prescribing an appropriately standardized and tested pharmaceutical formulation of cannabidiol.” 

“Dravet syndrome and Lennox-Gastaut syndrome are diagnosed in early childhood and represent some of the most difficult types of epilepsy to treat. 

“Nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime,” he said.

Shares rose 5% to US$117.6.

]]>
Mon, 05 Dec 2016 15:18:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/169972/gw-pharma-posts-more-good-data-from-epilepsy-trials-169972.html
<![CDATA[RNS press release - American Society of Epilepsy Annual Meeting ]]> http://www.proactiveinvestors.co.uk/companies/rns/161201gwp7013q/ Thu, 01 Dec 2016 11:15:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161201gwp7013q/ <![CDATA[RNS press release - Notice of Q4 and year-end results ]]> http://www.proactiveinvestors.co.uk/companies/rns/161130gwp4818q/ Wed, 30 Nov 2016 13:00:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161130gwp4818q/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161124gwp9985p/ Thu, 24 Nov 2016 07:30:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161124gwp9985p/ <![CDATA[RNS press release - Presenting at Piper Jaffray Healthcare Conference ]]> http://www.proactiveinvestors.co.uk/companies/rns/161122gwp8355p/ Tue, 22 Nov 2016 13:00:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161122gwp8355p/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161118gwp5683p/ Fri, 18 Nov 2016 09:31:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161118gwp5683p/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161111gwp0256p/ Fri, 11 Nov 2016 17:02:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161111gwp0256p/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161110gwp8768o/ Thu, 10 Nov 2016 11:03:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161110gwp8768o/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161103gwp2809o/ Thu, 03 Nov 2016 13:58:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161103gwp2809o/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161103gwp2259o/ Thu, 03 Nov 2016 07:50:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161103gwp2259o/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161103gwp2256o/ Thu, 03 Nov 2016 07:47:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161103gwp2256o/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161102gwp1855o/ Wed, 02 Nov 2016 17:05:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161102gwp1855o/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161101gwp9873n/ Tue, 01 Nov 2016 09:58:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161101gwp9873n/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161031gwp8986n/ Mon, 31 Oct 2016 15:29:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161031gwp8986n/ <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/161031gwp8957n/ Mon, 31 Oct 2016 14:59:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161031gwp8957n/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161031gwp8493n/ Mon, 31 Oct 2016 08:25:00 +0000 http://www.proactiveinvestors.co.uk/companies/rns/161031gwp8493n/ <![CDATA[RNS press release - Director Stock Trading Plan ]]> http://www.proactiveinvestors.co.uk/companies/rns/161028gwp7917n/ Fri, 28 Oct 2016 16:59:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161028gwp7917n/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161028gwp7912n/ Fri, 28 Oct 2016 16:58:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161028gwp7912n/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161026gwp5598n/ Wed, 26 Oct 2016 17:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161026gwp5598n/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/161025gwp4431n/ Tue, 25 Oct 2016 17:43:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161025gwp4431n/ <![CDATA[RNS press release - Posting of Shareholder Circular ]]> http://www.proactiveinvestors.co.uk/companies/rns/161021gwp2213n/ Fri, 21 Oct 2016 16:37:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161021gwp2213n/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/161020gwp0987n/ Thu, 20 Oct 2016 15:31:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161020gwp0987n/ <![CDATA[RNS press release - Intention to Trade Exclusively on NASDAQ ]]> http://www.proactiveinvestors.co.uk/companies/rns/161019gwp8903m/ Wed, 19 Oct 2016 07:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161019gwp8903m/ <![CDATA[RNS press release - Director Stock Trading Plan - Replacement ]]> http://www.proactiveinvestors.co.uk/companies/rns/161007gwp9993l/ Fri, 07 Oct 2016 10:22:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161007gwp9993l/ <![CDATA[RNS press release - Director Stock Trading Plan ]]> http://www.proactiveinvestors.co.uk/companies/rns/161006gwp9410l/ Thu, 06 Oct 2016 18:01:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/161006gwp9410l/ <![CDATA[News - GW Pharma still has the legs to get over a tenner, but pick your entry point ]]> http://www.proactiveinvestors.co.uk/companies/news/167020/gw-pharma-still-has-the-legs-to-get-over-a-tenner-but-pick-your-entry-point-167020.html GW Pharmaceuticals PLC (LON:GWP) has been on a tear of late – but is there any further upside to the stock?

Well, according to our charts guru Zak Mir, it could go as high as £10 a share (current price £8.77); however, Mir says it is worth picking your entry point.

“I would never pay more than the 10-day average, which is £8.23,” he said on the Proactive Investor Bulletin Board Show.   

“Ideally you are looking at dips to the 50-day line, which is way below [the 10-day average] at £6.29.” 

WATCH: Zak gives his verdict on the outlook for GWP

The shares have motored 315% higher since mid-March on the back of some positive results from a late-stage trial of a cannabis-derived drug that treats a severe form of childhood epilepsy.  

Recently, bid speculation has driven the stock on amid reports it has appointed an investment bank to screen interest in the company.  

“It has great fundamental backing and a great chart too,” Mir told host Nick Batsford.  

“We’ve had a rising trend channel and the big vertical move in March. We only retraced a third of that before it went up again   

“We have been gathering momentum ever since.   

“We have a target here even after all the gains as high as £10, given this rising trend channel we have seen.”  

GW, after this year’s performance is AIM’s third largest company with a value of £2.65bn.  

Last week the drug developer, which is also listed on the US tech exchange, NASDAQ, unveiled more pointers to the efficacy of Epidolex, for childhood seizures.  

Numis analyst Paul Cuddon called it “the most convincing ” data so far. It is expected GW will make a new drug application early next year.  

Last month investors were put on bid alert after a report from Reuters suggested the company had multiple potential suitors.  

The Reuters story also said GW had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.  

The interest was very firmly rooted around Epidiolex, which analysts reckon has the potential to deliver annual sales of around US$800mln.

The identities of the potential suitors were unknown; however, the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM). Analysts also reckon Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might be in the running.  

]]>
Thu, 06 Oct 2016 11:40:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/167020/gw-pharma-still-has-the-legs-to-get-over-a-tenner-but-pick-your-entry-point-167020.html
<![CDATA[Media files - GW Pharmaceuticals is going to £10 a share says King of Charts ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/6131/gw-pharmaceuticals-is-going-to-10-a-share-says-king-of-charts-6131.html Thu, 06 Oct 2016 10:16:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/6131/gw-pharmaceuticals-is-going-to-10-a-share-says-king-of-charts-6131.html <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/160930gwp3802l/ Fri, 30 Sep 2016 13:48:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160930gwp3802l/ <![CDATA[News - GW Pharmaceuticals data the "most convincing so far", says City heavyweight ]]> http://www.proactiveinvestors.co.uk/companies/news/166530/gw-pharmaceuticals-data-the-most-convincing-so-far-says-city-heavyweight-166530.html “Impressive so far”, is the verdict of one leading City broker, referring to the progress of GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH) and the results from its lead drug for a childhood epilepsy.

Numis, in a note, repeated its 835p valuation of stock in the druggie, which is at the cutting edge of cannabis-derived medicines.

The shares ended the week at 838.5p, up 20%.

The driver? GW unveiled more pointers to the efficacy of Epidolex, for childhood seizures.

Numis analyst Paul Cuddon called it “the most convincing ”data so far.

It is expected GW will make a new drug application early next year.

Earlier this month investors were put on bid alert after a report suggest the company had multiple potential suitors.

The Reuters story also said GW had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.

The interest was very firmly rooted around Epidiolex, which analysts reckon has the potential to deliver annual sales of around US$800mln.

The identities of the potential suitors were unknown.

However, the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM).

Numis, in an earlier broker note, reckoned Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might also be in the running.

In the year to date the stock has advanced 102%, buoyed by some encouraging headline results from a phase III clinical trial of Epidiolex.

On the back of that the company was able to raise £190mln from US investors to bankroll the further development of its lead product.

Valued at £2.4bn, GW is AIM’s third largest company.

]]>
Tue, 27 Sep 2016 11:03:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/166530/gw-pharmaceuticals-data-the-most-convincing-so-far-says-city-heavyweight-166530.html
<![CDATA[News - GW Pharmaceuticals seizure drug aces phase three trial ]]> http://www.proactiveinvestors.co.uk/companies/news/166462/gw-pharmaceuticals-seizure-drug-aces-phase-three-trial-166462.html GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) cannabinoid drug Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome - a severe form of childhood epilepsy - speeding through phase three trials.

Back in June, the group’s first pivotal phase three study of Epidiolex for the treatment of seizures in connection with the syndrome revealed favourable results. And then in March, the group released positive results in connection with Dravet syndrome.

Epidiolex was well tolerated during the trial period. The adverse pattern of events was in line with the previously reported two Phase 3 studies.

GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.

 "We feel a tremendous sense of urgency to stop seizures, and believe that the pursuit of new therapies offers hope to individuals who have no currently available therapy to effectively stop their seizures,” said chief executive Philip Gattone.

Shares trading on the London Stock Exchange rose 11% to 775.5p. 

]]>
Mon, 26 Sep 2016 14:25:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/166462/gw-pharmaceuticals-seizure-drug-aces-phase-three-trial-166462.html
<![CDATA[RNS press release - Second Positive Phase 3 Trial for Epidiolex in LGS ]]> http://www.proactiveinvestors.co.uk/companies/rns/160926gwp8260k/ Mon, 26 Sep 2016 11:57:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160926gwp8260k/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> http://www.proactiveinvestors.co.uk/companies/rns/160914gwp8758j/ Wed, 14 Sep 2016 17:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160914gwp8758j/ <![CDATA[News - Soaring cannabis stock primed and ready for a take-out ]]> http://www.proactiveinvestors.co.uk/companies/news/163662/soaring-cannabis-stock-primed-and-ready-for-a-take-out-163662.html Shares in GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH) were up almost 20% in afternoon trade amid reports the company has multiple potential suitors.

Investors were put on bid alert after it emerged the company had appointed Wall Street heavyweight Morgan Stanley to oversee the potential beauty parade.

The interest comes as the company as it prepares to bring to market Epidiolex, a cannabis-derived medication to treat a severe form of childhood epilepsy.

Analysts say the drug has the potential to deliver annual sales of around US$800mln.

According to Reuters, the financial news agency that broke the story, the identities of the potential GW Pharma suitors are unknown.

However it points out the big beasts in this sphere of the drugs market are Novartis (ETX:NOVN), Bayer (ETR:BAYN) and Almirall (BME:ALM).

However London broker Numis reckons Lundbeck (CPH:LUN), Otsuka (TYO:4578) and Biogen (NASDAQ:BIIB) might also be in the running.

Analyst  Paul Cuddon said: “With phase-three data on Epidiolex  (the key attraction)…due in the coming weeks and more data expected in December the timing is intriguing, allowing a potential acquirer an effective first option on the data.”

However he cautioned there are still “significant clinical, regulatory and commercial risks” associated with the treatment.

The shares, which are LSE and Nasdaq-quoted, were up 105p at 631.5p in a busy transatlantic trading session. That values the business at just shy of £2bn.

In the past six months the stock has advanced 178%, buoyed by some encouraging headline results from a phase III clinical trial of Epidiolex.

On the back of that the company was able to raise £190mln from US investors to bankroll the further development of its lead product.

]]>
Thu, 08 Sep 2016 14:22:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/163662/soaring-cannabis-stock-primed-and-ready-for-a-take-out-163662.html
<![CDATA[RNS press release - Presenting at Morgan Stanley Healthcare Conference ]]> http://www.proactiveinvestors.co.uk/companies/rns/160907gwp1203j/ Wed, 07 Sep 2016 12:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160907gwp1203j/ <![CDATA[RNS press release - Total Issued Share Capital ]]> http://www.proactiveinvestors.co.uk/companies/rns/160831gwp5715i/ Wed, 31 Aug 2016 12:19:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160831gwp5715i/ <![CDATA[RNS press release - Block listing Interim Review ]]> http://www.proactiveinvestors.co.uk/companies/rns/160817gwp4133h/ Wed, 17 Aug 2016 08:57:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160817gwp4133h/ <![CDATA[News - GW Pharmaceuticals's cannabidiol epilepsy drug ready for NDA filing ]]> http://www.proactiveinvestors.co.uk/companies/news/129158/gw-pharmaceuticals-s-cannabidiol-epilepsy-drug-ready-for-nda-filing-129158.html GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) said it was on track for an NDA (New Drug Application) filing for both its cannabis-derived Dravet Syndrome and Lennox-Gastaut Syndrome indications following positive Phase III trials.

“We believe that these Phase III data show that Epidiolex has the potential to provide a robust and clinically meaningful reduction in seizures in these highly treatment-resistant populations together with an acceptable safety and tolerability profile,” stated chief executive Justin Gover.

Last month, GW raised just over £200mln (US$273mln) from a follow-on offering.

“Our recent successful financing has provided GW with the necessary capital to move forward with confidence in preparing to execute a highly successful launch," added Gover.

The group reported losses for the nine months ended June of £46.7mln (US$62.2mln) compared to £32.3mln reported last year. It said the loss reflected investment in the Phase III pivotal trials program.

It ended the period with £191.2mln (US$254.3mln) cash and cash equivalents, down from the £234.9mln last reported in September.

GW is developing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex, or cannabidiol, derived from the cannabis plant.

The group also announced today that its chief medical officer Stephen Wright is to retire in May next year after serving 13 years on the board.

Wright was instrumental in the development of the cannabinoid drug and bringing the pushing the group towards a NASDAQ listing, said a statement Tuesday.

GW will look to hire a successor by May 2017.

]]>
Tue, 09 Aug 2016 13:02:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/129158/gw-pharmaceuticals-s-cannabidiol-epilepsy-drug-ready-for-nda-filing-129158.html
<![CDATA[RNS press release - 3rd Quarter Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/160809gwp6809g/ Tue, 09 Aug 2016 12:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160809gwp6809g/ <![CDATA[RNS press release - Notice of Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/160802gwp8904f/ Tue, 02 Aug 2016 12:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160802gwp8904f/ <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/160729gwp6729f/ Fri, 29 Jul 2016 10:59:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160729gwp6729f/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/160725gwp0875f/ Mon, 25 Jul 2016 07:58:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160725gwp0875f/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/160721gwp8582e/ Thu, 21 Jul 2016 10:08:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160721gwp8582e/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/160721gwp8577e/ Thu, 21 Jul 2016 10:05:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160721gwp8577e/ <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/160719gwp5771e/ Tue, 19 Jul 2016 09:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160719gwp5771e/ <![CDATA[RNS press release - Closing of U.S. Public Offering Raising $289.8m ]]> http://www.proactiveinvestors.co.uk/companies/rns/160718gwp4815e/ Mon, 18 Jul 2016 16:15:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160718gwp4815e/ <![CDATA[News - GW Pharma to raise quarter of a billion dollars from US investors ]]> http://www.proactiveinvestors.co.uk/companies/news/128143/gw-pharma-to-raise-quarter-of-a-billion-dollars-from-us-investors-128143.html The UK’s GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH), a world leader in cannabis-based medicines, has outlined plans to raise US$252mln from US investors.

It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.

The stock is being offer at US$90, a modest discount to last night’s closing price of US$97.

The company said it will file next year for regulatory approval in the US for Epidiolex, used to treat severe epilepsy in children, after what were described as “stellar” late stage clinical trial results.

]]>
Wed, 13 Jul 2016 08:24:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/128143/gw-pharma-to-raise-quarter-of-a-billion-dollars-from-us-investors-128143.html
<![CDATA[RNS press release - US Public Offering of ADSs Raising $252.0 Million ]]> http://www.proactiveinvestors.co.uk/companies/rns/160713gwp0119e/ Wed, 13 Jul 2016 07:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160713gwp0119e/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/160701gwp0356d/ Fri, 01 Jul 2016 15:15:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160701gwp0356d/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/160701gwp9315c/ Fri, 01 Jul 2016 08:03:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160701gwp9315c/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/160628gwp5065c/ Tue, 28 Jun 2016 12:15:00 +0100 http://www.proactiveinvestors.co.uk/companies/rns/160628gwp5065c/